The company operates three subsidiaries including Helomics, which provides tumor-analysis services for treatment personalization and new drug development.
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.
Treatment biomarkers for small cell lung cancer have been nearly non-existent, but researchers are beginning to find ones that mark PARP inhibitor response.
Pfizer expects its own trial of talazoparib for this new indication to wrap up in 2021, ideally recapitulating the positive results seen in this smaller group.
The companies will use their respective technologies to identify inhibitors of cancer-associated gene targets and optimize their use as therapeutics.
The company said it is on track to complete a clinical validation by the end of next year, after which it would launch its assay for clinical use.
The firm is developing a biomarker panel to detect mutations in mesenchymal cells, with the goal of guiding drug treatment and improving earlier patient intervention.
A proteogenomic analysis by a Moffitt Cancer Center-led team uncovered three subtypes of squamous cell lung cancer and treatment approaches to investigate.
The company has signed a new, multiyear agreement with the Korean health system to build a data sharing network to support precision cancer care in East Asia.
Biocartis' Idylla called some colorectal cancer samples negative that Sysmex Inostics's OncoBEAM called positive, but the clinical implications may be complex.